Dermican™ LS 9837 | BASF Latin America |
|
Dermican™ LS 9837 is a synthetic tetrapeptide that provides targeted action on dermal structure via stimulation of lumican and collagen synthesis. It creates a global restructuring of the skin matrix, which is clinically proven to improve skin thickness ...view more
Dermican™ LS 9837 is a synthetic tetrapeptide that provides targeted action on dermal structure via stimulation of lumican and collagen synthesis. It creates a global restructuring of the skin matrix, which is clinically proven to improve skin thickness and firmness. view less
Compliance Highlights Available
|
Request Sample |
Dermican™ PW LS 9838 | BASF Latin America |
|
Dermican™ PW LS 9838 is a synthetic tetrapeptide that provides targeted action on dermal structure via stimulation of lumican and collagen synthesis. It creates a global restructuring of the skin matrix, which is clinically proven to improve skin thickne...view more
Dermican™ PW LS 9838 is a synthetic tetrapeptide that provides targeted action on dermal structure via stimulation of lumican and collagen synthesis. It creates a global restructuring of the skin matrix, which is clinically proven to improve skin thickness and firmness. view less
Compliance Highlights Unavailable
|
Request Sample |
Peptiskin® | Solabia Group |
|
Peptiskin® is a 40% dry extract solution composed of L-lysine and L-arginine oligopeptides obtained by a biotechnological enzymatic synthesis process without using any solvent. This product is used as a triple action, global anti-aging peptide. It helps w...view more
Peptiskin® is a 40% dry extract solution composed of L-lysine and L-arginine oligopeptides obtained by a biotechnological enzymatic synthesis process without using any solvent. This product is used as a triple action, global anti-aging peptide. It helps with the stimulation of extracellular matrix structural component synthesis and deposit. It also aids in the inhibition of anarchic collagen crosslinking and the inhibition of metalloproteinase 1 (MMP-1 collagenase) release. view less
Compliance Highlights Unavailable
|